Last reviewed · How we verify
vincristine, cyclophosphamide, and doxorubicin
vincristine, cyclophosphamide, and doxorubicin is a Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development. Also known as: Onconvin and Cytoxan and Adriamycin.
At a glance
| Generic name | vincristine, cyclophosphamide, and doxorubicin |
|---|---|
| Also known as | Onconvin and Cytoxan and Adriamycin |
| Sponsor | St. Jude Children's Research Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vincristine, cyclophosphamide, and doxorubicin CI brief — competitive landscape report
- vincristine, cyclophosphamide, and doxorubicin updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI
Frequently asked questions about vincristine, cyclophosphamide, and doxorubicin
What is vincristine, cyclophosphamide, and doxorubicin?
vincristine, cyclophosphamide, and doxorubicin is a Small molecule drug developed by St. Jude Children's Research Hospital.
Who makes vincristine, cyclophosphamide, and doxorubicin?
vincristine, cyclophosphamide, and doxorubicin is developed by St. Jude Children's Research Hospital (see full St. Jude Children's Research Hospital pipeline at /company/st-jude-children-s-research-hospital).
Is vincristine, cyclophosphamide, and doxorubicin also known as anything else?
vincristine, cyclophosphamide, and doxorubicin is also known as Onconvin and Cytoxan and Adriamycin.
What development phase is vincristine, cyclophosphamide, and doxorubicin in?
vincristine, cyclophosphamide, and doxorubicin is in Phase 3.
Related
- Manufacturer: St. Jude Children's Research Hospital — full pipeline
- Also known as: Onconvin and Cytoxan and Adriamycin
- Compare: vincristine, cyclophosphamide, and doxorubicin vs similar drugs
- Pricing: vincristine, cyclophosphamide, and doxorubicin cost, discount & access